UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

Journal of the renin-angiotensin-aldosterone system, 2017-07, Vol.18 (3), p.1470320317717883-1470320317717883

2017

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

Frontiers in pharmacology, 2017-10, Vol.8, p.740-740

2017

Volltextzugriff (PDF)

A decade of innovation in pharmaceutical R&D: the Chorus model

Nature reviews. Drug discovery, 2015-01, Vol.14 (1), p.17-28

2015

Volltextzugriff (PDF)

Discovery of 6‑(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl‑1H‑indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Journal of medicinal chemistry, 2015-12, Vol.58 (24), p.9768-9772

2015

Volltextzugriff (PDF)

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587

Oncotarget, 2017-11, Vol.8 (55), p.94619-94634

2017

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations

The AAPS journal, 2014-09, Vol.16 (5), p.1009-1017

2014

Volltextzugriff (PDF)

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Clinical cancer research, 2014-07, Vol.20 (13), p.3581-3588

2014

Volltextzugriff (PDF)

Evaluation of a mathematical model of diabetes progression against observations in the Diabetes Prevention Program

American journal of physiology: endocrinology and metabolism, 2012-07, Vol.303 (2), p.E200-E212

2012

Volltextzugriff (PDF)

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Targeted oncology, 2017-08, Vol.12 (4), p.463-474

2017

Volltextzugriff (PDF)

Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects

Drug metabolism and disposition, 2016-09, Vol.44 (9), p.1536-1542

2016

Volltextzugriff (PDF)

Mathematical models of diabetes progression

American journal of physiology: endocrinology and metabolism, 2008-12, Vol.295 (6), p.E1462-E1479

2008

Volltextzugriff (PDF)

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Investigational new drugs, 2017-06, Vol.35 (3), p.334-344

2017

Volltextzugriff (PDF)

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7567-7567

2015

Volltextzugriff (PDF)

Chiral Capillary Electrophoretic Determination of 2′,3′-Dideoxy-5-fluoro-3′-thiacytidine in Rat Plasma

Journal of liquid chromatography & related technologies, 2003-11, Vol.26 (18), p.3037-3044

2003

Volltextzugriff (PDF)

Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects

Clinical pharmacology in drug development, 2021-05, Vol.10 (5), p.440-452

2021

Volltextzugriff (PDF)

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1 H -indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Journal of medicinal chemistry, 2015-12, Vol.58 (24), p.9768-9772

2015

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Alamifovir and Its Metabolites

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.1813-1822

2005

Volltextzugriff (PDF)

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e18558-e18558

2015

Volltextzugriff (PDF)

Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2019-01, Vol.18 (1), p.39-53

2019

Volltextzugriff (PDF)

Evaluation of a mathematical model of diabetes progression against observations in the Diabetes Prevention Program

American journal of physiology: endocrinology and metabolism, 2012, Vol.66 (1)

2012

Volltextzugriff (PDF)

Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy

Clinical pharmacology in drug development, 2018-09, Vol.7 (7), p.759-772

2018

Volltextzugriff (PDF)

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1[Beta] Antibody, in Patients With Type 2 Diabetes

Diabetes care, 2013-08, Vol.36 (8), p.2239

2013

Volltextzugriff (PDF)

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY21 89102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

Diabetes care, 2013-08, Vol.36 (8), p.2239

2013

Volltextzugriff (PDF)

Abstract 1419: A phase I study of the CXCR4 peptide antagonist LY2510924 in patients with advanced cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1419-1419

2013

Volltextzugriff (PDF)

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

Diabetes care, 2013-08, Vol.36 (8), p.2239-2246

2013

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

A decade of innovation in pharmaceutical R&D: the Chorus model

Discovery of 6‑(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl‑1H‑indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587

Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Evaluation of a mathematical model of diabetes progression against observations in the Diabetes Prevention Program

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects

Mathematical models of diabetes progression

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC)

Chiral Capillary Electrophoretic Determination of 2′,3′-Dideoxy-5-fluoro-3′-thiacytidine in Rat Plasma

Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1 H -indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Clinical Pharmacokinetics of Alamifovir and Its Metabolites

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts)

Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis

Evaluation of a mathematical model of diabetes progression against observations in the Diabetes Prevention Program

Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1[Beta] Antibody, in Patients With Type 2 Diabetes

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY21 89102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

Abstract 1419: A phase I study of the CXCR4 peptide antagonist LY2510924 in patients with advanced cancer

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

Suchergebnisse filtern